IL158649A0 - Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function - Google Patents

Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Info

Publication number
IL158649A0
IL158649A0 IL15864998A IL15864998A IL158649A0 IL 158649 A0 IL158649 A0 IL 158649A0 IL 15864998 A IL15864998 A IL 15864998A IL 15864998 A IL15864998 A IL 15864998A IL 158649 A0 IL158649 A0 IL 158649A0
Authority
IL
Israel
Prior art keywords
azabenzimidazole
protein kinase
based compounds
threonine protein
kinase function
Prior art date
Application number
IL15864998A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL158649A0 publication Critical patent/IL158649A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL15864998A 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function IL158649A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (1)

Publication Number Publication Date
IL158649A0 true IL158649A0 (en) 2004-05-12

Family

ID=22027657

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15864998A IL158649A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL135109A IL135109A (en) 1997-09-26 2000-03-15 Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en) 1997-09-26 2003-10-29 Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL135109A IL135109A (en) 1997-09-26 2000-03-15 Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en) 1997-09-26 2003-10-29 Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Country Status (28)

Country Link
US (2) US6093728A (xx)
EP (1) EP1017384B1 (xx)
JP (1) JP2001517699A (xx)
KR (1) KR100547929B1 (xx)
CN (1) CN1167420C (xx)
AR (1) AR017266A1 (xx)
AT (1) ATE281834T1 (xx)
AU (1) AU748849B2 (xx)
BG (1) BG64784B1 (xx)
BR (1) BR9812682A (xx)
CA (1) CA2305370C (xx)
DE (1) DE69827516T2 (xx)
DK (1) DK1017384T3 (xx)
ES (1) ES2230719T3 (xx)
HK (1) HK1032206A1 (xx)
HU (1) HUP0004024A3 (xx)
IL (4) IL158649A0 (xx)
NO (1) NO325663B1 (xx)
NZ (2) NZ503432A (xx)
PL (1) PL191618B1 (xx)
PT (1) PT1017384E (xx)
RU (1) RU2230553C2 (xx)
SK (1) SK285357B6 (xx)
TR (1) TR200001546T2 (xx)
TW (1) TW581815B (xx)
UA (1) UA72448C2 (xx)
WO (1) WO1999016438A1 (xx)
ZA (1) ZA988797B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2630920A1 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
ATE543819T1 (de) * 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
ES2662036T3 (es) * 2007-02-28 2018-04-05 Yeda Research And Development Company Limited Secuencias que se dirigen al núcleo
WO2008150015A1 (en) * 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (en) * 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2229391B1 (en) 2007-12-19 2014-08-06 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100184851A1 (en) * 2008-08-29 2010-07-22 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
MX341704B (es) 2009-10-26 2016-08-31 Signal Pharm Llc Métodos de síntesis y purificación de compuestos de heteroarilo.
PL2531502T3 (pl) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
CA2857155C (en) 2011-12-02 2021-09-21 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014113429A2 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
UA115805C2 (uk) 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
DK3191457T3 (da) 2014-09-12 2019-10-07 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDER SOM Kv7-KANALAKTIVATORER
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
EP0526488B1 (en) * 1990-04-02 1994-11-30 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU672224B2 (en) * 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
KR100547929B1 (ko) 2006-02-02
WO1999016438A1 (en) 1999-04-08
PL191618B1 (pl) 2006-06-30
KR20010015623A (ko) 2001-02-26
PT1017384E (pt) 2005-03-31
SK4152000A3 (en) 2002-02-05
IL135109A (en) 2007-07-04
ZA988797B (en) 1999-12-02
RU2230553C2 (ru) 2004-06-20
NZ517808A (en) 2003-07-25
TW581815B (en) 2004-04-01
JP2001517699A (ja) 2001-10-09
EP1017384A1 (en) 2000-07-12
IL135109A0 (en) 2001-05-20
TR200001546T2 (tr) 2000-10-23
CA2305370C (en) 2006-11-28
AU748849B2 (en) 2002-06-13
CN1278172A (zh) 2000-12-27
HUP0004024A3 (en) 2001-10-29
US6855723B2 (en) 2005-02-15
US20030181480A1 (en) 2003-09-25
SK285357B6 (sk) 2006-11-03
BG104356A (en) 2000-12-29
BG64784B1 (bg) 2006-04-28
BR9812682A (pt) 2000-08-22
EP1017384B1 (en) 2004-11-10
ATE281834T1 (de) 2004-11-15
NO20001555D0 (no) 2000-03-24
NO20001555L (no) 2000-03-24
IL158649A (en) 2006-12-10
NZ503432A (en) 2002-11-26
DK1017384T3 (da) 2005-01-31
AU9578198A (en) 1999-04-23
DE69827516D1 (de) 2004-12-16
NO325663B1 (no) 2008-07-07
AR017266A1 (es) 2001-09-05
CA2305370A1 (en) 1999-04-08
CN1167420C (zh) 2004-09-22
HK1032206A1 (en) 2001-07-13
PL339744A1 (en) 2001-01-02
ES2230719T3 (es) 2005-05-01
DE69827516T2 (de) 2005-12-01
HUP0004024A2 (hu) 2001-04-28
UA72448C2 (en) 2005-03-15
US6093728A (en) 2000-07-25

Similar Documents

Publication Publication Date Title
IL158649A0 (en) Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
HK1031836A1 (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxa-line-based compounds.
HUS1600018I1 (hu) Aril kondenzált azapoliciklusos vegyületek
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
IL134086A0 (en) Novel spiroazabicyclic heterocyclic compounds
GB9715892D0 (en) Heterocyclic compounds
IL132170A0 (en) Novel heterocyclic compounds
HUP0103079A3 (en) Modulating multiple lineage kinase proteins
ZA981920B (en) Novel heterocyclic compounds
AU6049399A (en) Serine/threonine protein kinases
AU6546098A (en) Serine/threonine protein kinase
AU6421498A (en) Serine/threonine protein kinase
GB9713732D0 (en) Substituted triazinic compounds
GB9803399D0 (en) Protein kinase c
GB9716101D0 (en) Fused heterocyclic compounds
PL336639A1 (en) Novel heterocyclic compounds
ZA983669B (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
IL136872A0 (en) Organosilane compounds
GB9715734D0 (en) Heterocyclic compounds
ZA981177B (en) Heterocyclic compounds
GB9801058D0 (en) Heterocyclic compounds
GB9719237D0 (en) Heterocyclic compounds
GB9716378D0 (en) Heterocyclic compounds
GB9715735D0 (en) Heterocyclic compounds

Legal Events

Date Code Title Description
KB Patent renewed
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees